No significant deterioration in health-related quality of life in patients with melanoma brain metastases treated with immunotherapy
May 8, 2023
Abstract
Aims:
To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab–nivolumab or nivolumab treatment.
Materials & methods:
HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan–Meier method was used to determine median time to first deterioration.
Results:
Asymptomatic MBM patients treated with ipilimumab–nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement.
Conclusion:
MBM patients treated with either ipilimumab–nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation.
Source:
Thompson, J. R., Lai-Kwon, J., Morton, R. L., Guminski, A. D., Gonzalez, M., Atkinson, V., Sandhu, S., Brown, M. P., Menzies, A. M., McArthur, G. A., Lo, S. N., Long, G. V., & Bartula, I. (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy. https://doi.org/10.2217/imt-20...